Brief: Newamsterdam Pharma Says Full Data From Phase 2 Rose2 Trial Evaluating Obicetrapib In Combination With Ezetimibe As An Adjunct To High-Intensity Statin Therapy

NewAmsterdam Pharma

03/06/2023 17:20

June 3 (Reuters) - NewAmsterdam Pharma Company NV
 NAMS.O :
    * NEWAMSTERDAM PHARMA PRESENTS FULL DATA FROM PHASE 2 ROSE2
TRIAL
EVALUATING OBICETRAPIB IN COMBINATION WITH EZETIMIBE AS AN
ADJUNCT TO HIGH-INTENSITY STATIN THERAPY AT NLA SCIENTIFIC
SESSIONS 2023
    * NEWAMSTERDAM PHARMA COMPANY NV SAYS MET PRIMARY ENDPOINT
WITH
63.4% MEDIAN REDUCTION IN LDL-C (P<0.0001)
    * NEWAMSTERDAM PHARMA COMPANY NV SAYS SELECTED FIXED-DOSE
COMBINATION TABLET FORMULA; PHASE 3 TRIAL EXPECTED TO INITIATE
1Q 2024
    * NEWAMSTERDAM -87.1% PATIENTS TREATED WITH BOTH
OBICETRAPIB,EZETIMIBE MET LDL-C GOAL OF <55 MG/DL VERSUS 0% OF
PATIENTS TREATED WITH PLACEBO

Source text for Eikon:  ID:nGNXkkbzG 
Further company coverage:  NAMS.O 

 ((Reuters.Briefs@thomsonreuters.com;))